Last reviewed · How we verify
NCT03756220: ATESS
Ascorbic Acid and Thiamine Effect in Septic Shock
Phase 2 trial testing Combination therapy of vitamin C and thiamine in Septic Shock in 116 participants. Completed in 14 April 2020.
13 January 2020
Quick facts
| Lead sponsor | Tae Gun Shin |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 116 |
| Start date | 1 December 2018 |
| Primary completion | 13 January 2020 |
| Estimated completion | 14 April 2020 |
| Sites | 6 locations across South Korea |
Drugs / interventions tested
- Combination therapy of vitamin C and thiamine — full drug profile →
- Normal saline solution
Conditions studied
- Septic Shock — all drugs for Septic Shock →
- Sepsis — all drugs for Sepsis →
Sponsor
Tae Gun Shin — full company profile →
Who can join
Adults 19 to 89, any sex, with Septic Shock or Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelial Activation and Microcirculatory Disorders in Sepsis.
Raia L, Zafrani L. · · 2022 · cited 34× · PMID 35721048 · DOI 10.3389/fmed.2022.907992 -
Combination therapy of vitamin C and thiamine for septic shock in a multicentre, double-blind, randomized, controlled study (ATESS): study protocol for a randomized controlled trial.
Hwang SY, Park JE, Jo IJ, Kim S, et al · · 2019 · cited 15× · PMID 31296251 · DOI 10.1186/s13063-019-3542-x -
Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial.
Park JE, Jo YH, Hwang SY, Kim WY, et al · · 2022 · cited 5× · PMID 34482319 · DOI 10.1097/shk.0000000000001850
Verify or expand the search:
- PubMed search for NCT03756220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Septic Shock
Currently open trials in the same condition.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
- NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03756220 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tae Gun Shin
- Last refreshed: 28 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03756220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing